TITLE

National Formulary

PUB. DATE
January 2005
SOURCE
Taber's Cyclopedic Medical Dictionary;2005, p1431
SOURCE TYPE
Book
DOC. TYPE
Reference Entry
ABSTRACT
The article offers information on the National Formulary. It is a collection of officially recognized drug names originally issued by the American Pharmaceutical Association, but is currently published by the U.S. Pharmacopeial Convention. The information is from the "Taber's Cyclopedic Medical Dictionary," published by F.A. Davis Co.
ACCESSION #
21237201

 

Related Articles

  • Pharmacy resources on the World Wide Web.  // Pharmacy Today;Dec2004, Vol. 10 Issue 12, p19 

    This article focuses on the pharmacy resources on the world wide web. Recommendations for Comparing Electronic Prescribing Systems, this report from the journal Health Affairs presents and ranks 60 recommended capabilities of e-prescribing systems. The recommendations were considered by a panel...

  • New in the marketplace.  // Drugs & Therapy Perspectives;Oct2006, Vol. 22 Issue 10, p26 

    The article presents a lists of product approvals identified in international markets including the gemifloxacin and octocog-alfa.

  • Changes to Preferred Drug Program Take Effect in February.  // NYSDA NEWS;Feb2008, Vol. 21 Issue 1, p11 

    The article reports on the approval of the changes in the preferred or non-preferred status of certain drugs subject to New York's Preferred Drug Program (PDP). As reported the changes were recommended by the Medicaid Pharmacy and Therapeutics Committee, which were later approved by State Health...

  • Effects of Bilastine on T-wave Morphology and the QTc Interval. Graff, Claus; Struijk, Johannes J.; Kanters, Jørgen K.; Andersen, Mads P.; Toft, Egon; Zyl, Benoft // Clinical Drug Investigation;2012, Vol. 32 Issue 5, p339 

    Background and Objectives: The International Conference of Harmonisation (ICH) El4 guideline for thorough QT studies requires assessing the propensity of new non-antiarrhythmic drugs to affect cardiac repolarization. The present study investigates whether a composite ECG measure of T-wave...

  • Making Design Validation Effective. Bandurek, Goerge R. // BioPharm International;Mar2005 Supplement, Vol. 18, p18 

    Focuses on the effectiveness of the design validation in the production of pharmaceutical products. Importance of verification tests in the design validation; Containment of the product specification in delivering the right amount of drug in the right form to the right place; Principal element...

  • Analytical Method Validation for Biopharmaceuticals. Krause, Stephan O. // BioPharm International;Mar2005 Supplement, Vol. 18, p26 

    Focuses on the importance of analytical method validation in the biopharmaceutical industry for all methods used to test final containers, raw materials, in-process materials and excipients. Regulatory guidelines and elements of analytical method development; Details of the guidance for...

  • SELECTION OF LICENSING CANDIDATES IN THE PHARMACEUTICAL INDUSTRY: AN APPLICATION OF THE ANALYTIC HIERARCHY PROCESS. Ross, Michael E.; Nydick, Robert L. // Journal of Health Care Marketing;Jun92, Vol. 12 Issue 2, p60 

    The ethical (prescription) pharmaceutical industry depends on a stream of innovative, patent-protected products to maintain growth and profitability. With Sterling Drug's entry into a new therapeutic area (oncology, the study and treatment of cancer), licensing and research collaborations have...

  • Generics may profit pharmacists.  // Marketing News;9/16/2002, Vol. 36 Issue 19, p14 

    This article reports that Blue Cross and Blue Shield of Illinois has announced plans to pay pharmacists every time they convince a consumer to switch from a brand name drug to a generic. Generic drugs generally cost much less than brand-name versions. For instance, the generic version of the...

  • Be sure your technology is up to the task. Sveum, Jerry // Pharmacy Today;Dec2004, Vol. 10 Issue 12, p24 

    This article focuses on four software features that are necessary to ensure this and that allow for efficient management of 340B drug supply. Entities without an in-house pharmacy that want to participate in the 340B Drug Pricing Program can contract with a local pharmacy to make discounted...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics